| Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. | |
| | |
MedLine Citation:
|
PMID: 20658156 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Hyperlipidemia, insulin resistance, and oxidative stress can heavily contribute to the initiation and progression of nonalcoholic fatty liver disease (NAFLD). Currently, there is no established treatment for this disease. Recently, several studies have shown that ezetimibe (EZ), a lipid-lowering drug, attenuates liver steatosis in an experimental NAFLD model. This study was designed to assess the efficacy of long-term EZ monotherapy in patients with NAFLD. METHODS: A total of 45 patients with newly diagnosed liver biopsy-proven NAFLD were treated with EZ (10 mg/day) for 24 months. NAFLD-related biochemical parameters, imaging by computerized tomography, and liver biopsy were studied before and after treatment. RESULTS: Ezetimibe therapy significantly improved NAFLD-related metabolic parameters including visceral fat area, fasting insulin, homeostasis model assessment of insulin resistance (HOMA-R), triglycerides, total cholesterol, low-density lipoprotein cholesterol (LDL-Ch), oxidative-LDL, the net electronegative charge modified-LDL, profiles of lipoprotein particle size and fatty acids component, and estimated desaturase activity. EZ therapy also significantly lowered serum alanine aminotransferase and high-sensitivity C-reactive protein levels, whereas no significant changes were found in serum type IV collagen 7S, adiponectin, leptin, and resistin levels. Histological features of steatosis grade (P = 0.0003), necroinflammatory grade (P = 0.0456), ballooning score (P = 0.0253), and NAFLD activity score (NAS) (P = 0.0007) were significantly improved from baseline. However, the fibrosis stage was not significantly (P = 0.6547) changed. CONCLUSION: The results in this study suggest that the long-term EZ therapy can lead to improvement in metabolic, biochemical, and histological abnormalities of NAFLD. Therefore, EZ may be a promising agent for treatment of NAFLD. |
| | |
Authors:
|
Hyohun Park; Toshihide Shima; Kanji Yamaguchi; Hironori Mitsuyoshi; Masahito Minami; Kohichiroh Yasui; Yoshito Itoh; Toshikazu Yoshikawa; Michiaki Fukui; Goji Hasegawa; Naoto Nakamura; Mitsuhiro Ohta; Hiroshi Obayashi; Takeshi Okanoue |
Related Documents
:
|
17194266 - Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and ... 20105136 - Cross-talk between exogenous statins and endogenous high-density lipoprotein in anti-in... 12162466 - Pharmacology of 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors (statins), i... 11731186 - Estrogen/progesterone replacement versus pravastatin and their sequential association i... 15490266 - Effect of dietary-induced metabolic acidosis and ovariectomy on bone mineral density an... 16332646 - Maternal cholesterol in fetal development: transport of cholesterol from the maternal t... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't Date: 2010-07-24 |
Journal Detail:
|
Title: Journal of gastroenterology Volume: 46 ISSN: 1435-5922 ISO Abbreviation: J. Gastroenterol. Publication Date: 2011 Jan |
Date Detail:
|
Created Date: 2011-01-14 Completed Date: 2011-04-20 Revised Date: 2011-05-13 |
Medline Journal Info:
|
Nlm Unique ID: 9430794 Medline TA: J Gastroenterol Country: Japan |
Other Details:
|
Languages: eng Pagination: 101-7 Citation Subset: IM |
Affiliation:
|
Department of Gastroenterology and Hepatology, Saiseikai Suita Hospital, 1-2 Kawazono-cho, Suita, Osaka, 564-0013, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Anticholesteremic Agents / administration & dosage, therapeutic use* Azetidines / administration & dosage, therapeutic use* Biological Markers / blood Biopsy Drug Administration Schedule Fatty Liver / blood, drug therapy, pathology Female Humans Liver / pathology Liver Cirrhosis / classification, pathology Male Middle Aged Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Anticholesteremic Agents; 0/Azetidines; 0/Biological Markers; 163222-33-1/ezetimibe |
| Comments/Corrections | |
Comment In:
|
J Gastroenterol. 2011 Mar;46(3):415-6; author reply 417
[PMID:
21181211
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Efficacy of mosapride citrate in proximal gastric accommodation and gastrointestinal motility in hea...
Next Document: Increased hexosamine pathway flux and high fat feeding are not additive in inducing insulin resistan...